Therapeutic potential of phosphoinositide 3-kinase inhibitors

Chemistry and Biology

Volumn 10, Issue 3, 2003, Pages 207-213

  Ward, Stephen ^a   Sotsios, Yannis ^a   Dowden, James ^a   Bruce, Ian ^b   Finan, Peter ^a  

^a UNIVERSITY OF BATH   (United Kingdom)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0037350266     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(03)00048-6     Document Type: Review

References (58)

1. Whitman M., Downes C.P., Keeler M., Cantley L.C. Type I phosphatidylinositol makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature. 332:1998;644-646.
2. Courtneidge S.A., Heber A. An 81-kd protein complexed with middle T-antigen and pp60c-src - a possible phosphatidylinositol kinase. Cell. 50:1987;1031-1037.
3. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2000;1655-1657.
4. Vanhaesebroeck B., Leevers S.J., Ahmadi K., Timms J., Katso R., Driscoll P.C., Woscholski R., Parker P.J., Waterfield M.D. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70:2000;535-602.
5. Stephens L.R., Eguinoa A., Erdjument-Bromage H., Lui M., Cooke F., Coadwell J., Smrcka A.S., Thelen M., Cadwallader K., Tempst P., Hawkins P.T. The Gβγ sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell. 89:1997;105-114.
6. Yart A., Roche S., Wetzker R., Laffargue M., Tonks N., Mayeux P., Chap H., Raynal P. A function for phosphoinositide 3-kinase-β lipid products in coupling βγ to Ras activation in response to lysophosphatidic acid. J. Biol. Chem. 277:2000;21167-21178.
7. Sotsios Y., Ward S.G. Phosphoinositide 3-kinase. a key biochemical signal for cell migration in response to chemokines Immunol. Rev. 177:2000;217-235.
8. Kurosu H., Maehama T., Okada T., Yamamoto T., Hoshino S., Fukui Y., Ui M., Hazeki O., Katada T. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110β is synergistically activated by the βγ subunits of G proteins and phosphotyrosyl peptide. J. Biol. Chem. 272:1996;24252-24256.
9. Domin J., Pages F., Volinia S., Rittenhouse S.E., Zvelebil M.J., Stein R.C., Waterfield M.D. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem. J. 326:1997;139-147.
10. Gaidarov I., Smith M.E.K., Domin J., Keen J.H. The class II phosphoinositide 3-kinase C2-α is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol. Cell. 7:2001;443-449.
11. Rohrschneider L.R., Fuller J.F., Wolf I., Liu Y., Lucas D.M. Structure, function and biology of SHIP proteins. Genes Dev. 14:2000;505-520.
12. Cantley L.C., Neel B.G. New insights into tumour suppression. PTEN suppresses tumour formation by restraining the phosphoinositide 3-kinase/Akt pathway Proc. Natl. Acad. Sci. USA. 96:2000;4240-4245.
13. Wishart M.J., Dixon J.E. PTEN and myotubularin phosphatases. from 3-phosphoinositide dephosphorylation to disease Trends Cell Biol. 12:2002;579-585.
14. Ward S.G., June C.H., Olive D. PI 3-kinase. a pivotal pathway in T cell activation Immunol. Today. 17:1996;187-197.
15. Wymann M.P., Bulgarelli-Leva G., Zvelebil M.J., Pirola L., Vanhaesebroeck B., Waterfield M.D., Panayotou G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16:1996;1722-1733.
16. Matter W.F., Brown R.F., Vlahos C.J. The inhibition of phosphatidylinositol 3-kinase by quercetin and its analogs. Biochem. Biophys. Res. Commun. 186:1992;624-631.
17. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) J. Biol. Chem. 269:1994;5241-5248.
18. Toledo L.M., Lydon N.B., Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 6:1999;775-805.
19. Garcia-Echeverria C., Traxler P., Evans D.B. ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev. 20:2000;28-57.
20. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., Williams R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell. 6:2000;909-919.
21. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:2000;95-105.
22. Hayakaa, M., Kaizawa, H., Kawaguchi, K.I., Matsuda, K., Ishikawa, N., Koizumi, T., Yamanao, M., and Ohta, M. June 2002. Therapeutic morpholino-substituted compounds. U.S. patent 6,403,588 B1.
23. Robertson, A.J., Jackson, S., Kenche, V., Yaip, C., Parbaharan, H., and Thompson, P. July 2001. Preparation and formulation of morpholino-substituted heterocycles as phosphoinositide 3-kinase inhibitors for therapeutic use. International patent application WO 0153266 A1.
24. Sadhu, C., Dick, K., Treiberg, J., Sowell, C.G., Kesicki, E.A., and Oliver A. November 2001. Quinazolinone derivatives as inhibitors of human phosphatidylinositol 3-kinase delta. International patent application WO 0181346 A2.
25. Foukas L.C., Daniele N., Ktori C., Andersen K.E., Jensen J., Shepherd P. Direct effects of caffeine and theophylline on p110delta and other phosphoinositide 3-kinases. J. Biol. Chem. 277:2002;37124-37130.
26. Wang F., Herzmark P., Weiner O.D., Srinivasan S., Servant G., Bourne H.R. Lipid products of PI(3)Ks maintain persistent cell polarity and directed motility in neutrophils. Nat. Cell Biol. 4:2002;513-518.
27. Weiner O.D., Neilsen P.O., Prestwich G.D., Kirschner M.W., Cantley L.C., Bourne H.R. A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat. Cell Biol. 4:2002;509-512.
28. Iijima M., Devreotes P. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell. 109:2002;599-610.
29. Funamoto S., Meili R., Lee S., Parry L., Firtel R.A. Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell. 109:2002;611-623.
30. Sasaki T., Irie-Sasaki J., Jones R.G., Oliveira-dos-Santos A.J., Stanford W.L., Bolon B., Wakeham A., Itie A., Bouchard D., Kozieradzki I.et al. Function of PI3Kγ in thymocyte development, T cell activation and neutrophil migration. Science. 287:2000;1040-1044.
31. Hirsch E., Katanaev V.L., Garlanda C., Azzolino O., Pirola L., Silengo L., Sozzani S., Mantovani A., Altruda F., Wymann M. Central role for G protein-coupled phosphoinostide 3-kinase-γ in inflammation. Science. 287:2000;1049-1053.
32. Li Z., Jiang H., Zie W., Zhang Z., Smrcka A.V., Wu D. Roles of PLC-β2 and β-3 and PI3Kγ in chemoattractant-mediated signal transduction. Science. 287:2000;1046-1049.
33. Helgason C.D., Damen J.E., Rosten P., Grewal R., Sorensen P., Chappel S.M., Borowski A., Jirik F., Humphries R.K. Targeted disruption of SHIP leads to hemopoietic perturbations in lung pathology, and a shortened life span. Genes Dev. 12:1998;1610-1620.
34. Okkenhaug K., Bilancio A., Farjot G., Priddle H., Sancho S., Peskett E., Pearce W., Meek S.E., Salpekar A., Waterfield M.D.et al. Impaired B and T cell antigen receptor in p110δ PI 3-kinase mutant mice. Science. 297:2002;1031-1034.
35. Laffargue M., Calvez R., Finan P., Trifilieff A., Barbier M., Altruda F., Hirsch E., Wymann M.P. Phosphoinositide 3-kinase-γ is an essential amplifier of mast cell function. Immunity. 16:2002;441-451.
36. Rittenhouse S.E. Phosphoinositide 3-kinase and platelet function. Blood. 88:1996;4401-4414.
37. Hirsch E., Bosco O., Tropel P., Laffargue M., Calvez R., Altruda F., Wymann M.P., Montruchhio G. Resistance to thromboembolism in PI3Kγ-deficient mice. FASEB J. 15:2001;2019-2022.
38. Crackower M.A., Oudit G.Y., Kozieradzki I., Sarao R., Hirsch E., Suzuki A., Shioi T., Irie-Sasaki J., Sah R., Cheng H.Y.M.et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN pathways. Cell. 10:2002;737-749.
39. Northcott C.A., Poy M.N., Najjar S.M., Watts S.W. Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ. Res. 91:2002;360-369.
40. Sata M., Nagai R. Phosphatidylinositol 3-kinase. a key regulator of vascular tone Circ. Res. 91:2002;273-275.
41. Shayesteh L., Lu Y.L., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21:1999;99-102.
42. Ma Y.Y., Wei S.J., Lin Y.C., Lung J.C., Chang T.C., Whang-Peng J., Liu J.M., Yang D.M., Yang W.K., Schen C.Y. PIK3CA as an oncogene in cervical cancer. Oncogene. 19:2000;2739-2744.
43. Simpson L., Parsons R. Pten. Life as a tumor suppressor Exp. Cell Res. 264:2002;29-41.
44. Testa J.R., Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA. 98:2002;10983-10985.
45. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., Lee J.H., Ciarallo S., Catzavelos C., Beniston R.et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8:2002;1153-1160.
46. Shin I., Yakes F.M., Rojo F., Shin N.Y., Bakin A.V., Baselga J., Arteaga C.L. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 8:2002;1145-1152.
47. Viglietto G., Motti M.L., Bruni P., Melillo R.M., D'Alessio A., Califano D., Vinci F., Chiappetta G., Tsichlis P., Bellacosa A.et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8:2002;1136-1144.
48. Mayo L.D., Donner D.B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 27:2002;462-467.
49. Hu L.M., Hofmann J., Lu Y.L., Mills G.B., Jaffe R.B. Inhibition of phosphatidylinositol 3-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62:2000;1087-1092.
50. Schultz R.M., Merriman R.L., Andis S.L., Bonjouklian R., Grindey G.B., Rutherford P.G., Gallegos A., Massey L., Powis G. In-vitro and in-vivo anti-tumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 15:1995;1135-1139.
51. Hosoi Y., Miyachi H., Matsumoto Y., Ikehata H., Komura J., Ishii K., Zhao H.J., Yoshida M., Takai Y., Yamada S.et al. A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation. Int. J. Cancer. 78:1998;642-647.
52. Edwards E., Geng L., Tan J., Onishko H., Donnelly E., Hallahan D.E. Phosphatidylinositol 3-kinase/Akt signalling in the response of vascular endothelium to ionizing radiation. Cancer Res. 62:2002;4671-4677.
53. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N.et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:2001;50-56.
54. Shioi T., Kang P.M., Douglas P.M., Hampe J., Yballe C.M., Lawitts J., Cantley L.C., Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19:2000;2537-2548.
55. Shioi T., McMullen J.R., Kang P.M., Douglas P.S., Obata T., Franke T.F., Cantley L.C., Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22:2002;2799-2809.
56. Matsui T., Li L., Wu J.C., Cook S.A., Nagoshi T., Picard M.H., Liao R., Rosenzweig A. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 277:2002;22896-22901.
57. Matsui T., Tao J., del Monte F., Lee K.H., Li L., Picard M., Force T.L., Franke T.F., Hajjar R.J., Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 104:2001;330-335.
58. Fujio Y., Nguyen T., Wencker D., Kitsis R.N., Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 101:2001;660-667.